[go: up one dir, main page]

CU23679A1 - Variantes de pertactinas para uso vacunal - Google Patents

Variantes de pertactinas para uso vacunal

Info

Publication number
CU23679A1
CU23679A1 CU20070240A CU20070240A CU23679A1 CU 23679 A1 CU23679 A1 CU 23679A1 CU 20070240 A CU20070240 A CU 20070240A CU 20070240 A CU20070240 A CU 20070240A CU 23679 A1 CU23679 A1 CU 23679A1
Authority
CU
Cuba
Prior art keywords
engineering
vaccines
pertactin
pertactines
vaccine
Prior art date
Application number
CU20070240A
Other languages
English (en)
Inventor
Leal Yoelys Cruz
Medina Tamara Menendez
Acosta Anabel Alvarez
Vazquez Diogenes Quintana
Nieto Gerardo Enrique Guillen
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20070240A priority Critical patent/CU23679A1/es
Priority to BRPI0817898 priority patent/BRPI0817898A2/pt
Priority to EP08845509A priority patent/EP2216045A1/en
Priority to PCT/CU2008/000009 priority patent/WO2009056076A1/es
Priority to US12/739,658 priority patent/US8569470B2/en
Priority to RU2010121646/10A priority patent/RU2499046C2/ru
Priority to KR1020107011928A priority patent/KR20100093548A/ko
Priority to CN2008801141194A priority patent/CN101878038B/zh
Priority to CA2702697A priority patent/CA2702697A1/en
Priority to MX2010004706A priority patent/MX2010004706A/es
Priority to ARP080104709A priority patent/AR069086A1/es
Publication of CU23679A1 publication Critical patent/CU23679A1/es
Priority to US13/966,948 priority patent/US20140011216A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se enmarca en el campo de la biomedicina, y comprende la ingenierización de la proteína pertactina (Prn) para su obtención y uso en vacunas bacterianas, más particularmente en vacunas acelulares contra Bordetella pertussis. Las pertactinas ingenierizadas abarcan en su estructura el polimorfismo de diferentes cepas, y al ensayarse como vacunas inducen una respuesta de anticuerpos de mayor capacidad protectora y de mayor actividad opsonofagocítica. Las variantes ingenierizadas de pertactina de esta invención son aplicables en la medicina humana y veterinaria.
CU20070240A 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal CU23679A1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
CU20070240A CU23679A1 (es) 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal
RU2010121646/10A RU2499046C2 (ru) 2007-10-30 2008-10-17 Полинуклеотидная последовательность, кодирующая сконструированный белок пертактин, вектор, включающий такую последовательность, и вакцинные композиции, содержащие белок пертактина или вектор
EP08845509A EP2216045A1 (en) 2007-10-30 2008-10-17 Engineered pertactin variants for vaccine use
PCT/CU2008/000009 WO2009056076A1 (es) 2007-10-30 2008-10-17 Variantes ingenierizadas de pertactina para uso vacunal
US12/739,658 US8569470B2 (en) 2007-10-30 2008-10-17 Engineered pertactin variants for vaccine use
BRPI0817898 BRPI0817898A2 (pt) 2007-10-30 2008-10-17 Sequência polinucleotídica, composição farmacêutica, vacina, vetor de expressão em mamíferos, vacina, método para a deteccção de infecção por bordetella, e, kit diagnóstico para a detecção de presença ou ausência de anticorpos contra bordetella
KR1020107011928A KR20100093548A (ko) 2007-10-30 2008-10-17 백신 용도의 유전자 조작된 퍼탁틴 변이체
CN2008801141194A CN101878038B (zh) 2007-10-30 2008-10-17 用于疫苗用途的经改造的百日咳杆菌粘附素变体
CA2702697A CA2702697A1 (en) 2007-10-30 2008-10-17 Engineered pertactin variants for vaccine use
MX2010004706A MX2010004706A (es) 2007-10-30 2008-10-17 Variantes ingenierizadas de pertactina para uso vacunal.
ARP080104709A AR069086A1 (es) 2007-10-30 2008-10-28 Variantes ingenierizadas de pertactina para uso vacunal
US13/966,948 US20140011216A1 (en) 2007-10-30 2013-08-14 Engineered pertactin variants for vaccine use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20070240A CU23679A1 (es) 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal

Publications (1)

Publication Number Publication Date
CU23679A1 true CU23679A1 (es) 2011-07-11

Family

ID=40473455

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20070240A CU23679A1 (es) 2007-10-30 2007-10-30 Variantes de pertactinas para uso vacunal

Country Status (11)

Country Link
US (2) US8569470B2 (es)
EP (1) EP2216045A1 (es)
KR (1) KR20100093548A (es)
CN (1) CN101878038B (es)
AR (1) AR069086A1 (es)
BR (1) BRPI0817898A2 (es)
CA (1) CA2702697A1 (es)
CU (1) CU23679A1 (es)
MX (1) MX2010004706A (es)
RU (1) RU2499046C2 (es)
WO (1) WO2009056076A1 (es)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2160120C2 (ru) * 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
ES2303833T3 (es) * 2000-05-25 2008-09-01 Institut Pasteur Polipeptidos que contienen polimorfismos de las regiones repetidas de pertactina en bordetella pertussis, bordetella parapertussis y bordetella bronchiseptica, su uso en diagnostico y en composiciones inmunogenicas.
EP1174505A1 (en) 2000-06-30 2002-01-23 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur (Poly)peptides for the preparation of vaccines against Bordetella pertussis and/or Bordetella parapertussis, vaccines based upon such (poly)peptides, and antibodies against such peptides
AU2004277342B2 (en) * 2003-10-02 2010-12-16 Glaxosmithkline Biologicals S.A. Pertussis antigens and use thereof in vaccination

Also Published As

Publication number Publication date
RU2010121646A (ru) 2011-12-10
AR069086A1 (es) 2009-12-30
BRPI0817898A2 (pt) 2015-05-05
US20110070265A1 (en) 2011-03-24
WO2009056076A1 (es) 2009-05-07
RU2499046C2 (ru) 2013-11-20
CN101878038B (zh) 2013-11-06
US20140011216A1 (en) 2014-01-09
US8569470B2 (en) 2013-10-29
KR20100093548A (ko) 2010-08-25
MX2010004706A (es) 2010-05-27
CA2702697A1 (en) 2009-05-07
CN101878038A (zh) 2010-11-03
EP2216045A1 (en) 2010-08-11

Similar Documents

Publication Publication Date Title
IL294095A (en) Methods of producing human rpe cells and pharmaceutical preparations of human rpe cells
BR112012020863A2 (pt) formas de rifaximina e usos das mesmas
GT200600240A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos
BRPI0919958A2 (pt) balão de cateter radiopaco deformável e resistente à ruptura e métodos para uso do mesmo em um procedimento cirúrgico intravascular
BRPI1013432A2 (pt) derivado de indolizina e uso do mesmo para propósitos médicos
ECSP077888A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
UY32812A (es) Anticuerpos humanos de alta afinidad para angiopoyetina -2 humana.
CO6640258A2 (es) Formulaciones de anticuerpos de alta concentración
AR075913A1 (es) Metodo para preparar un conjugado polipeptidico fisiologicamente activo de sitio especifico
CR11731A (es) Composiciones y procedimientos para su preparación y uso
GT201300080A (es) Proceso de elaboracion para derivados de pirimidina
CR10654A (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
BRPI0912292A2 (pt) composições e métodos para o uso de células no tratamento do tecido cardíaco.
CL2015001342A1 (es) Compuestos derivados de pirrolo[3,2-d]pirimidina; composicion farmaceutica y de vacuna que los comprende y el uso en el tratamiento de enfermedades alergicas y otras enfermedades inflamatorias, infecciosas y cancer.
DOP2015000162A (es) Anticuerpos anti-lamp1 y conjugados anticuerpo fármaco, y usos de éstos
MX381271B (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana
MX2020005235A (es) Celula humana transformada y uso de la misma.
EP2391390A4 (en) COMPLEX OF BIFUNCTIONAL CHELAT BALDNER AND MANNOSYL HSA
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
BR112012003760A2 (pt) Sistema de cultura de explante de pele humana e uso do mesmo
WO2010053610A3 (en) Stable anthrax vaccine formulations
AR087811A1 (es) Vacuna contra el staphylococcus aureus
IT1398768B1 (it) Uso di microrna-199b-5p in campo medico e diagnostico.
BR112012018840A2 (pt) proteínas recombinantes para uso em vacina, anticorpos contra as ditas proteínas e métodos de diagnósticos e terapêuticos incluindo as mesmas

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)